Introduction
Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is a commonly occurring enzyme defect classically associated with acute hemolytic crises following contact with or ingestion of fava beans (favism) or certain drugs, chemicals or infection. 1 No less serious is the dreaded complication in neonates of severe hyperbilirubinemia, with the devastating potential of bilirubin encephalopathy or kernicterus.
2-4 G-6-PD deficiency is included by the Subcommittee on Hyperbilirubinemia of the American Academy of Pediatrics among the major risk factors for severe neonatal hyperbilirubinemia. 5 The following case report, based on a true case, illustrates how G-6-PD deficiency, especially when in combination with additional risk factors, may potentiate sudden, acute onset of extreme hyperbilirubinemia resulting in irreversible, permanent brain damage.
Case report BE, a 36-week gestation, 3403-g male infant was born in Canada to immigrants from the Mediterranean region. Pregnancy had been normal. The baby was delivered vaginally by vacuum extraction. Apgar scores were 9 and 9 at 1 and 5 min, respectively. The baby was admitted to the regular nursery, where the receiving nurse noted his skin color to be normal. The admitting physician designated a 'normal baby' diagnosis. The baby nursed satisfactorily, passed sufficient stool and urine and was discharged as healthy at age 46 h. Skin color was not documented at discharge and a predischarge bilirubin determination was not performed. During the first post-discharge day the baby appeared to be doing well. On the fourth day of life, skin color changes were noted. The pediatrician was called and the baby was diagnosed with cutis marmorata based on the mother's description. The baby was neither examined nor referred to medical assessment. Later that day, when the color changes persisted, the mother took him to the local emergency room, where he was noted by the triage nurse to have the 'color of a pumpkin'. Shortly after arrival, the baby started seizing and stopped breathing. He required full resuscitation, ventilation and admission to the neonatal intensive care unit. The serum bilirubin concentration was 38.2 mg per 100 ml. The baby underwent exchange transfusion, following which the serum bilirubin values decreased and hyperbilirubinemia did not recur. Today the baby is severely and irreversibly neurologically and developmentally disabled. The clinical picture is compatible with that of kernicterus. The baby was subsequently found to be G-6-PD deficient.
What went wrong in the management of this infant boy, and could the kernicterus have been prevented? Although predischarge bilirubin testing was not performed, none of the nurses caring for the baby in hospital had documented a yellow skin color. It appears more than likely, therefore, that there was very little visible jaundice at the time of discharge. The knowledge that the baby was G-6-PD deficient may not have prevented contact with the (unidentified) material, which presumably triggered the hemolysis and resulted in severe hyperbilirubinemia. However, had the parents been aware of the G-6-PD deficiency state and the baby's high-risk status for sudden and acute onset of jaundice, they might have sought medical assistance earlier, and the possibility of acute hemolysis would have been considered before the development of extreme hyperbilirubinemia. The breast-feeding baby was not designated preterm, both being factors with a high risk for developing hyperbilirubinemia. This combination of risk factors, including prematurity, breast-feeding, early discharge and G-6-PD deficiency, unrecognized by the medical/nursing team caring for the baby, undoubtedly placed the baby at risk for severe, unpredictable neonatal hyperbilirubinemia with its tragic outcome.
The relationship of G-6-PD deficiency with severe neonatal hyperbilirubinemia and kernicterus The function of the enzyme and clinical aspects of G-6-PD deficiency have been well described and are beyond the scope of this paper. 1, 3, 4, 6 The enzyme G-6-PD plays a major role in neutralizing reactive oxygen species, which may cause oxidative tissue damage.
1,6 G-6-PD plays an important role in the glutathione antioxidation system, catalyzing the reduction of NADP to NADPH, thereby allowing oxidized glutathione to be reverted to its reduced form, thus enabling it to continue its antioxidative role. In the absence of G-6-PD the glutathione and catalase antioxidant systems may not function, and in the presence of oxidative stress they may become insufficient to neutralize the large amounts of reactive oxygen species produced. The red blood cell is particularly susceptible to oxidative damage, which may result in hemolysis with a resultant additional bilirubin load.
G-6-PD deficiency and neonatal hyperbilirubinemia
Severe neonatal hyperbilirubinemia and kernicterus in association with G-6-PD deficiency has been noted in many geographical areas to which G-6-PD deficiency is indigenous, and also wherever individuals whose families originated in these areas reside today (Figure 1 ). The incidence of neonatal hyperbilirubinemia is several-fold greater in G-6-PD-deficient neonates than in G-6-PD-normal newborns, and may vary between population groups and between different geographical areas. 7 The most severe form of jaundice may be of sudden onset, the result of acute hemolysis akin to favism, due to contact with a sometimes identifiable chemical trigger or infection. The jaundice is unpredictable, and as the infant may have been nonicteric at the time of discharge from hospital predischarge bilirubin testing may not predict this form of hyperbilirubinemia. Exchange transfusion may be the only recourse to decrease the serum total bilirubin or prevent its further increase. Owing to its sudden and unpredictable onset, this form of G-6-PD-deficiency-associated neonatal hyperbilirubinemia may be the one etiologic factor preventing the total elimination of kernicterus.
More commonly, and probably of less danger to the neonate, is a more gradual form of jaundice. This type of hyperbilirubinemia usually responds to phototherapy, although exchange transfusion may occasionally be required. 8, 9 Predischarge screening has been shown to be of value in predicting this form of hyperbilirubinemia ( Figure 2 ). 10 The pathogenesis of the hyperbilirubinemia appears to be a combination of some degree of increased bilirubin production, 12, 13 Figure 1 Map showing worldwide distribution of G-6-PD deficiency. From WHO Working Group, 6 with permission.
with a predilection for diminished bilirubin conjugation 14, 15 due to the presence of the variant (TA) 7 promoter in the gene encoding the bilirubin-conjugating enzyme UDP-glucuronosyltransferase 1A1, associated with Gilbert syndrome in adults. 16 Any additional factor either increasing heme catabolism or further diminishing bilirubin conjugation may jeopardize the infant by further increasing production-conjugation imbalance, thereby potentiating severe hyperbilirubinemia.
Distribution and frequency of G-6-PD deficiency
Countries with a high incidence of G-6-PD deficiency G-6-PD deficiency is a public health concern of enormous proportions. It has been estimated that 200 to 400 million people worldwide are affected by G-6-PD deficiency, and that 7.5% of the global population carry one or two genes for the condition. 1, 6 The accompanying map shows the distribution throughout the world ( Figure 1 ). As it is an X-linked condition, the frequency of functional G-6-PD deficiency is expressed as the proportion of males in any given population found to be hemizygous for the condition. A further 10% of the enzyme-deficient population comprises female homozygotes, and an additional 10% are heterozygotes who may be functionally G-6-PD deficient due to unequal X-chromosome inactivation.
High-risk groups in countries with low incidence of G-6-PD deficiency Owing to migration patterns and modern ease of travel, G-6-PD deficiency can no longer be regarded as a condition limited to the areas marked on the map and may nowadays be encountered in virtually any corner of the globe. Furthermore, the frequencies noted in the accompanying map represent the frequencies of the entire population of a country or geographical area and do not take subgroups with a high incidence of G-6-PD deficiency into account. For example, in the United States, although the overall incidence is noted to be <3.0%, African Americans are affected to the extent of 11 to 13%, 8, 17 and as many as 22% of South East Asians may be enzyme deficient. 18 In Israel, in the subgroup of Jews whose families immigrated from Asia Minor, the overall incidence may be as high as 27%, 9 and even twice that figure among certain subgroups. Recent trends in population migration should therefore be closely monitored. It was pointed out at the Siena conference that G-6-PD deficiency was virtually unencountered in that city several decades ago, whereas nowadays, due to influx of families from southern Italy and Sardinia, G-6-PD deficiency is a not an uncommon cause of neonatal hyperbilirubinemia (Bracci R, personal communication). When evaluating a neonate with unexplained jaundice, it is therefore important to ascertain the family background and test for G-6-PD deficiency when appropriate. A list of subgroups of the North American and European populations at risk for G-6-PD deficiency appears in Table 1 .
G-6-PD deficiency in countries with a low incidence of the condition G-6-PD deficiency has traditionally been regarded as a condition limited to the Mediterranean region, the Middle East and Asia. In the United States, Brown et al. 19 found that physicians practicing in the New York area frequently did not relate to the condition in their assessment of neonatal hyperbilirubinemia, whereas more recently, G-6-PD deficiency was not included in scoring systems designed to predict hyperbilirubinemia. 20, 21 However, evidence is mounting that even in countries previously felt to be at low risk for G-6-PD deficiency the condition can no longer be ignored. Several case reports of kernicterus in G-6-PD-deficient neonates have been described in North America. [22] [23] [24] [25] In a report of the Pilot USA Kernicterus Registry, 26 of 125 (20.8%) neonates were G-6-PD deficient, whereas, of a subset of 61 neonates readmitted for severe hyperbilirubinemia and kernicterus, G-6-PD deficiency was present Figure 2 Incidence of hyperbilirubinemia, defined as serum total bilirubin concentration >15.0 mg/dl for G-6-PD-deficient versus control neonates, stratified according to the predischarge bilirubin percentile, plotted on the hour-of-life-specific nomogram. 11 The incidence of hyperbilirubinemia was very low in those with bilirubin values <50th percentile, but increased progressively as the percentile range increased from 50th percentile through >90th percentile. 26, 27 Five of eight neonates with kernicterus whose families had immigrated from South East Asia, recently reported from Toronto, Canada, were deficient in the enzyme. 28 In a survey of the Canadian Paediatric Surveillance Program, of 93 newborns in whom a cause could be found for their severe hyperbilirubinemia, 20 were G-6-PD deficient. 29 Thus, the high incidence of G-6-PD deficiency in the neonatal population with severe hyperbilirubinemia or kernicterus contrasts sharply with the background incidence in these countries (Figure 1) . In a study of an African American cohort, exclusive breast feeding, G-6-PD deficiency and predischarge plasma total bilirubin X75th percentile were found to be significant risk factors for developing hyperbilirubinemia, whereas prematurity, mixed breast-formula feeding, cephalhematoma or bruising, or birth weight X4.0 kg, were not significant factors. 30 Both the Canadian Paediatric Society 31 and the US-based American Academy of Pediatrics 5 have recently published national guidelines for the prevention and management of neonatal hyperbilirubinemia. In both sets of recommendations, G-6-PD deficiency is recognized as a major cause of neonatal hyperbilirubinemia. Both recommend testing for G-6-PD deficiency in cases of otherwise unexplained hyperbilirubinemia, or when the family background suggests the possibility of the condition. Only the Canadian group recommends screening selected at-risk infants for the condition in the absence of hyperbilirubinemia. Table 2 summarizes the points raised by the Subcommittee on Hyperbilirubinemia of the American Academy of Pediatrics with regard to G-6-PD deficiency. Despite these recommendations, the Subcommittee recognized that immediate laboratory determination of G-6-PD status is generally not available at present in most US hospitals, and that it may be difficult to translate their statements and recommendations regarding G-6-PD deficiency into clinical practice.
Neonatal screening for G-6-PD deficiency As G-6-PD-deficient neonates are subject to sudden, unpredictable hemolytic crises, it is unlikely that screening programs for G-6-PD deficiency will totally abolish the neurological sequelae associated with the condition. However, knowledge that their infant has G-6-PD deficiency should increase the awareness of parents, as well as medical and nursing caretakers, about the risk of hyperbilirubinemia. Early seeking of medical assistance, determination of the total serum bilirubin in neonates who are becoming jaundiced, and prompt referral for phototherapy or exchange transfusion may all be instrumental in decreasing the serum bilirubin level before the manifestation of clinical signs of bilirubin encephalopathy. Predischarge bilirubin testing may be an adjunct in the prediction of hyperbilirubinemia.
10 Breast-feeding mothers should be warned to avoid offending drugs or fava, triple dye or menthol-containing umbilical potions, not to apply henna to the skin or use clothes that had been stored in naphthalene.
32-34
Effect of neonatal G-6-PD screening programs Although there have been many reports regarding the methodology of neonatal G-6-PD-deficiency screening and the incidence of the condition in various population groups, very few studies have actually assessed the effect of screening on the prevention of hyperbilirubinemia and the elimination of kernicterus. Institution of neonatal screening programs for G-6-PD deficiency, in combination with parental education regarding the risks of their infant developing severe hyperbilirubinemia, did lead to a decrease in the incidence of hyperbilirubinemia and kernicterus in Singapore, 35 Greece 34,36 and Saudi Arabia. 37 Although the effect on the incidence of neonatal jaundice was not specifically studied in Sardinia, the institution of neonatal G-6-PD screening in combination with adult education, including the warning to avoid eating fava beans, was responsible for a 75% decrease in the incidence of favism in children. 38 Currently, G-6-PD deficiency is being screened for primarily in some Asian, African, Mediterranean, Middle Eastern and European countries, where the prevalence of this condition is high. The inclusion of G-6-PD screening was recently debated by a committee designated by the American College of Medical Genetics to recommend a uniform newborn screening panel. G-6-PD deficiency was omitted from the screen on the grounds that the Table 2 Summary of points raised by the Subcommittee on Hyperbilirubinemia of the AAP with regard to G-6-PD deficiency 5 1. Measurement of G-6-PD level is recommended for a jaundiced infant who is receiving phototherapy and whose family history or ethnic or geographic origin suggest the likelihood of G-6-PD deficiency, or in a an infant, in whom the response to phototherapy is poor. 2. It is an option to test for G-6-PD deficiency in infant receiving phototherapy or in whom the total serum bilirubin (TSB) rising rapidly (crossing percentiles). G-6-PD testing is recommended if TSB is approaching exchange levels or not responding to phototherapy. 3. The Subcommittee recognizes that G-6-PD deficiency is today widespread and that immigration and intermarriage have transformed the condition into a global problem. 4. The high incidence (11-13%) of G-6-PD deficiency in African Americans is acknowledged. Hyperbilirubinemia in an African-American infant should raise the possibility of G-6-PD deficiency, as African Americans, as a group, have lower TSB levels than white or Asian infants. 5. G-6-PD deficiency is considered the cause of hyperbilirubinemia in 19 of 61 (31.5%) of recently reported, readmitted infants who developed kernicterus. 28 6. G-6-PD deficiency is listed among the major risk factors for the development of severe hyperbilirubinemia. 7. The subcommittee stresses the importance of looking for G-6-PD deficiency in infants with significant hyperbilirubinemia, as some of these may develop a sudden increase in TSB. G-6-PD deficient neonates require intervention at lower levels of TSB than G-6-PD normal counterparts.
natural history of G-6-PD mutations in the United States and their association with kernicterus and severe hemolytic crises are not clearly understood. 39 In the United States, G-6-PD deficiency is screened for in Washington, DC and in Pennsylvania.
Universal neonatal G-6-PD screening versus high-risk group screening As there was no lack of unanimity regarding the need to expand neonatal G-6-PD screening, there was a debate at the Siena conference regarding the advantages of universal screening compared with limited screening of high-risk groups only. A consensus was not reached. The advantage of universal screening by biochemical methods is that virtually all enzyme-deficient males (hemizygotes) and females (homozygotes) can be detected. Unfortunately, only a fraction of female heterozygotes will be identified. Previously thought to be at very low risk for the complications and dangers of G-6-PD deficiency, these female neonates are now recognized to have an incidence of hyperbilirubinemia close to that of their homozygote counterparts, 40 and may also be affected by acute hemolytic crises. 41, 42 In countries or geographical areas with a low overall incidence of the condition, universal G-6-PD screening will require many neonates to be tested at considerable cost, with relatively low yield. On the other hand, universal screening will identify affected neonates born to parents who have intermarried between ethnic groups with resultant mixing of genes, and will categorize those born to temporary residents or individual immigrants to a specific area who might otherwise be missed. Limiting the screening to high-risk groups requires taking an accurate history regarding the origin of parents' families, and may become less accurate as intermarriage between subgroups increases. On the other hand, financial savings may be substantial using this strategy.
Timing of G-6-PD screening There was consensus in Siena that, for G-6-PD screening to be effective in preventing severe hyperbilirubinemia and kernicterus, results of the screening program should be available to parents before discharge from the birth hospitalization. This will allow them time to receive instruction and education with regard to the condition, and will facilitate planning in conjunction with medical personnel, for the eventuality that their baby should become jaundiced. Umbilical cord blood provides a useful source of test material, but to meet a 48-h discharge deadline, most hospitals will be required to set up a daily G-6-PD testing service with quick turn-around time, a facility for which few hospitals in low-risk areas are prepared. Sampling babies at the time of routine metabolic screening and shipping the samples to a central laboratory may be cost efficient, but will compromise the benefit of early delivery of the results. Considering that the majority of neonates in the Pilot USA Kernicterus Registry were readmitted within the first week of life, 26 the earlier stratagem is undoubtedly preferable.
Biochemical versus molecular DNA screening For the purpose of mass screening, many qualitative biochemical tests are available. 6 Unless commercial kits are used, the reagents are cheap, and the main costs are related to manpower. 43 The WHO recommends a fluorescent technique as the preferred test, but this method requires specialized equipment, which may not always be available in the field, especially in developing countries. We compared commercially available color reduction and fluorescent test kits with quantitative G-6-PD activity, and found a similar degree of accuracy between the two. 11 Recently, Lin et al. 44 have developed a DNA-based newborn screening assay for the detection of G-6-PD gene mutations commonly encountered in the United States. These mutations include G-6-PD AÀ (G202A; A376G), G-6-PD Mediterranean (C563T) and two Chinese mutations (G1376T and G1388A). The authors estimate that by their method, about 90% of all affected infants should be identified in the US population. The advantages of this method include the ability to identify female heterozygotes, and the fact that dried blood spots are collected on filter paper and are thus not subjected to inactivation by heat exposure en route to the laboratory. However, in our opinion, the delay in obtaining results until about 1 week of life, and the fact that about 10% of G-6-PD-deficient neonates in the United States will be missed by this technique, makes this technique unsuitable for comprehensive neonatal G-6-PD screening with rapid turn-around time.
Conclusions
The WHO recommends neonatal screening on umbilical cord blood in populations in whom the incidence of G-6-PD deficiency in males exceeds 3-5%. 6 Undoubtedly, this aim should be our minimal goal. The question arises as to the need for more comprehensive screening in countries with a low overall incidence of G-6-PD deficiency. Our personal feeling, taking financial and manpower constraints into consideration, and in the absence of recent studies in countries assessing the effect of introduction of screening programs, is that at present, G-6-PD deficiency screening should be performed in high-risk groups only. However, there was a feeling among some of the participants at the conference that universal screening should be aimed for globally.
At present, we recommend that some form of G-6-PD screening should be available in most countries, and that G-6-PD deficiency should be taken into account when assessing the risk of a particular infant for developing hyperbilirubinemia. Availability of the test should be improved to allow on-site evaluation of already hyperbilirubinemic neonates. Further research needs to be performed to determine the effect of screening in diminishing the incidence of severe hyperbilirubinemia and kernicterus. In any society, the pros and cons of universal versus high-risk group screening should be weighed against the overall incidence of G-6-PD deficiency, presence of high-risk subgroups, incidence of severe hyperbilirubinemia and kernicterus, the need for exchange transfusion and the financial resources available.
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